Unknown

Dataset Information

0

Metabolic Imaging Detects Resistance to PI3K? Inhibition Mediated by Persistent FOXM1 Expression in ER+ Breast Cancer.

ABSTRACT: PIK3CA, encoding the PI3K? isoform, is the most frequently mutated oncogene in estrogen receptor (ER)-positive breast cancer. Isoform-selective PI3K inhibitors are used clinically but intrinsic and acquired resistance limits their utility. Improved selection of patients that will benefit from these drugs requires predictive biomarkers. We show here that persistent FOXM1 expression following drug treatment is a biomarker of resistance to PI3K? inhibition in ER+ breast cancer. FOXM1 drives expression of lactate dehydrogenase (LDH) but not hexokinase 2 (HK-II). The downstream metabolic changes can therefore be detected using MRI of LDH-catalyzed hyperpolarized 13C label exchange between pyruvate and lactate but not by positron emission tomography measurements of HK-II-mediated trapping of the glucose analog 2-deoxy-2-[18F]fluorodeoxyglucose. Rapid assessment of treatment response in breast cancer using this imaging method could help identify patients that benefit from PI3K? inhibition and design drug combinations to counteract the emergence of resistance.

SUBMITTER: Ros S 

PROVIDER: S-EPMC7562820 | biostudies-literature | 2020 Oct

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

PIK3CA, encoding the PI3Kα isoform, is the most frequently mutated oncogene in estrogen receptor (ER)-positive breast cancer. Isoform-selective PI3K inhibitors are used clinically but intrinsic and acquired resistance limits their utility. Improved selection of patients that will benefit from these drugs requires predictive biomarkers. We show here that persistent FOXM1 expression following drug treatment is a biomarker of resistance to PI3Kα inhibition in ER<sup>+</sup> breast cancer. FOXM1 dri  ...[more]

Similar Datasets

Unknown Cell Line-Specific Network Models of ER<sup>+</sup> Breast Cancer Identify Potential PI3Kα Inhibitor Resistance Mechanisms and Drug Combinations.
| S-EPMC8744502 | biostudies-literature
Genomics FOXM1 is a biomarker of resistance to PI3Kα inhibition in ER+ breast cancer that is detectable using metabolic imaging (RNA-seq data)
| EGAS00001004452 | EGA
Unknown Metabolic imaging of pancreatic ductal adenocarcinoma detects altered choline metabolism.
| S-EPMC4297549 | biostudies-literature
Unknown PDK1-SGK1 Signaling Sustains AKT-Independent mTORC1 Activation and Confers Resistance to PI3Kα Inhibition.
| S-EPMC4982440 | biostudies-literature
Unknown Hyperpolarized Metabolic Imaging Detects Latent Hepatocellular Carcinoma Domains Surviving Locoregional Therapy.
| S-EPMC7307779 | biostudies-literature
Unknown Inhibition of lysine acetyltransferase KAT6 in ER<sup>+</sup>HER2<sup>-</sup> metastatic breast cancer: a phase 1 trial.
| S-EPMC11333285 | biostudies-literature
Unknown Hormonal Regulation of Semaphorin 7a in ER<sup>+</sup> Breast Cancer Drives Therapeutic Resistance.
| S-EPMC7878309 | biostudies-literature
Unknown Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRAS<sup>G12C</sup> Inhibition.
| S-EPMC7124991 | biostudies-literature
Unknown Hyperpolarized [1,4-<sup>13</sup>C]fumarate imaging detects microvascular complications and hypoxia mediated cell death in diabetic nephropathy.
| S-EPMC7295762 | biostudies-literature
Unknown Nuclear FGFR1 Regulates Gene Transcription and Promotes Antiestrogen Resistance in ER<sup>+</sup> Breast Cancer.
| S-EPMC8338892 | biostudies-literature